Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.

Key facts

Study ID

NCT00962065

Run by

Lexicon Pharmaceuticals

People needed

36

Starts

2009-08-01

Last updated by the study team

2011-03-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females (non-childbearing potential), aged 18-65 years
• Diagnosis of Type 2 diabetes mellitus for at least 6 months prior to screening
• Fasting plasma glucose ≤ 240 mg/dL prior to metformin washout
• Body mass index < 42 kg/m\^2
• HbA1c value of 7 to 11%
• C-peptide ≥ 1.0 ng/mL
• Ability to provide written informed consent

You may not qualify if…

• History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, incontinence, or nocturia
• Use of any blood glucose lowering agent other than metformin
• Prior exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening
• Laboratory or electrocardiogram abnormalities deemed significant by the Sponsor or the Investigator
• Positive test result for glutamic acid decarboxylase (GAD) antibody
• Surgery within 6 months of screening
• Exposure to any investigational agent or participation in any investigational trial within 30 days prior to Day 1
• Hypersensitivity to an SGLT2 inhibitor
• History of drug or alcohol abuse within the last 12 months

Where it is running

• Lexicon Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.